* You are viewing Posts Tagged ‘Personal Health Record’

Google Glass Videos Coming Soon to Your Personal Health Record

One of the near-term technologies soon be seen in the doctor’s office is Google Glass, being tested now by the medical community among its earlier adopters. Its present retail cost will make adoption by consumers difficult at present, but as more tech-savvy users experiment and discover applications for Google Glass, its professional and consumer acceptance will grow as the retail price comes down.

Continue Reading

Mobile Health Communications Unleashed

With widespread adoption of handheld devices, such as the iPad®, iPhone® and Smartphones by consumers and physicians, Rob Dhoble closes the gap between information technology and achieving engagement between health professionals and patients to deliver measurable, improved outcomes. Rob is president of Omnicom’s Diversified Agency Services Health group.

Rob logs on to view his invention on a laptop, but he can also use a Smartphone or other handheld device with Internet access.

He bridges the divide with his patent pending mobile solution that … Continue Reading

Rethinking the Gene Patent Article

One of the most popular podcasts in the Health Thought Leadership series, here is the link to Alan Morrison’s article as a PDF, Rethinking the Gene Patent, published in the Biotechnology Law Report. The article accompanies the November 2010 post and podcast on the Myriad decision rendered by the U.S. District Court for the Southern District of New York.

Read why Alan reasons that “the court did not properly apply existing law. Instead it relied on what appears to be a new and problematic doctrine excluding isolated DNA from the realm of … Continue Reading

Rethinking the Gene Patent

In March 2010, Pandora’s box was opened when a federal District Court judge invalidated patent claims of Myriad Genetics, Inc., directed to two isolated human genes associated with breast cancer. These genes are used in genetic tests that Myriad has on the market for breast cancer. The tests cost over $3000 each. Their cost is not universally reimbursed. Therefore, the tests are not accessible to many women as a diagnostic tool. Without a license, other companies cannot develop an alternative, competitive test to provide a second opinion.

The controversy brings to a head many legal, ethical, and policy issues, … Continue Reading

Affording the Future Mix of Medication Therapies

With some biologic medications costing $100,000 or more annually, to treat a patient with a serious chronic illness, how will payers and patients afford the accelerating shift towards biologics?

Rising Expenditures for Biologic Medications

Dramatic increases ahead for spending on biologics.

Randy Vogenberg, RPh, PhD, noted consultant, author, and executive director of the Biologic Finance & Access Council Program at Philadelphia’s Thomas Jefferson University’s School of Population Health discusses how payers’ benefit design strategies may help more patients afford costly biologics and specialty medication therapies for chronic … Continue Reading